INZ-701
Asset
Recombinant ENPP1 fusion protein increases extracellular pyrophosphate to inhibit pathological mineralization.
- Stage
- Phase 1
- Modality
- Protein or enzyme
- Target
- ENPP1
- 3
- Indications
- 1
- Trial
- 1
- Developer
Indications
3Atp-binding cassette subfamily c member 6 deficiency
Phase 1, Completed, NCT05030831, clinicaltrials.gov, 15 Oct 2026
Generalized arterial calcification of infancy
Phase 1, Completed, NCT05030831, clinicaltrials.gov, 15 Oct 2026
Pseudoxanthoma elasticum
Phase 1, Completed, NCT05030831, clinicaltrials.gov, 15 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials1
- Evidence for its targets1
- Competitors1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.